Financings in Brief: Epix Medical
This article was originally published in The Gray Sheet
Executive SummaryEpix Medical: Cambridge, Massachusetts-based developer of magnetic resonance imaging contrast agents, formerly called Metasyn, files registration statement with the Securities and Exchange Commission for an initial public offering of up to 2 mil. shares. Epix' lead product is MS-325, an injectable agent for vascular imaging currently in clinical trials. Proceeds from the IPO will support "research and development, clinical trials, working capital requirements and other general corporate purposes," the firm says. Hambrecht & Quist and Wessels, Arnold & Henderson are co-managing...
You may also be interested in...
Biogen value-based contract with UPMC Health Plan ties payments to patient-reported outcomes for Tecfidera and Avonex. The company may seek something similar for Vumerity.
As interest in immune/inflammatory disease increases and savings achieved dip, payer focus on patient-reported outcomes for contracts reflects shift in focus, Avalere survey suggests.
After an eleventh-hour win last year that saw Congress repeal the medical device excise tax, AdvaMed is going more global. CEO Scott Whitaker sat down with Medtech Insight for a lengthy chat about what the lobby group will focus on in 2020, including reimbursement challenges, the upcoming medical device user-fee negotiations, and negotiations with governments that are key to the industry ecosystem.